Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pacira's Exparel: US FDA Panel Narrowly Rejects Nerve Block Claim

Feb 16 2018

• By Sue Sutter

FDA entrance sign 2016

Related Content

Pacira's Exparel Faces Efficacy Questions On Nerve Block Indication

Feb 12 2018

FDA Makes Broad Concessions In Settling Pacira Promotion Suit

Dec 15 2015

First Amendment Suit From Pacira Challenges FDA Labeling Interpretation

Sep 10 2015

Related Companies

Pacira BioSciences, Inc.

Additional Topics

United States Advisory Committees Drug Review Regulation BioPharmaceutical Neurology

More from US FDA Performance Tracker

More from Regulatory Trackers

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window